Analysis for GILD

📈 Growth & Financial Trajectory

Over the 8-quarter window from 2024Q2 through 2026Q1, Revenues are largely flat, moving from about $6.95B to $6.96B. Net Income progressed from roughly $1.78B in 2024Q2 to about $2.02B in 2026Q1, with a pronounced peak near $3.05B in 2025Q3 before easing in 2025Q4 and 2026Q1. The period shows a modest but meaningful improvement in profitability despite flat top-line growth.

The trend highlights episodic strength in mid-2025 and sustained cash-flow generation, but with a limited cumulative top-line expansion. Margins improved notably during the mid-year peak, helping translate earnings gains into cash generation.

💰 Margins & Cash Flow

Gross Margin remained robust, roughly in the high-70s to mid-80s percent range across the eight quarters (roughly 79%–93% per the data), supporting earnings resilience. Operating Margin fluctuated around 32%–43%, with a peak near 2025Q3 (~43%).

Cash flow was healthy: Net Cash Flow From Operating Activities was consistently positive, ranging from about $0.8B to $4.1B per quarter. Investing cash flow was typically negative, while financing activities varied; overall, quarterly free cash flow available in several periods supported balance-sheet resilience.

🛡️ Balance Sheet & Liquidity

Liquidity has improved meaningfully. The Current Ratio trended up, finishing near 2.0x in 2026Q1, indicating stronger short-term coverage. The company maintains substantial Long-term Debt ($22–$25B) alongside equity in the low-to-mid $20B range, with total liabilities in the ~$37–39B band, suggesting solid leverage management and cushion through cash generation.

⚠️ Key Drivers & Risks

• Drivers: Stable branded pharma cash flows; high gross margins supported by mature product lines and ongoing operating leverage.
• Risks: Regulatory/patent-driven cycle risks, competitive pressures, and sensitivity to macro conditions; modest revenue growth could constrain valuation upside absent pipeline catalysts.